Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Efficacy of carvacryl acetate in vitro and following oral administration to mice harboring either prepatent or patent Schistosoma mansoni infections

Full text
Author(s):
Silva, Bianca C. [1] ; Mengarda, Ana C. [1] ; Rodrigues, Vinicius C. [1] ; Cajas, Rayssa A. [1] ; Carnauba, Paulo U. [1] ; Espirito-Santo, Maria Cristina C. [2, 3] ; Bezerra-Filho, Carlos S. M. [4] ; de Sousa, Damiao P. [4] ; de Moraes, Josue [1]
Total Authors: 9
Affiliation:
[1] Univ Guarulhos, Nucleo Pesquisa Doencas Negligenciadas, R Eng Prestes Maia 88, BR-07023070 Guarulhos, SP - Brazil
[2] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Lab Imunopatol Esquistossomose LIM06, Sao Paulo, SP - Brazil
[3] Univ Sao Paulo, Inst Med Trop Sao Paulo, Lab Helmintol, Sao Paulo, SP - Brazil
[4] Univ Fed Paraiba, Dept Ciencias Farmaceut, Joao Pessoa, PB - Brazil
Total Affiliations: 4
Document type: Journal article
Source: Parasitology Research; v. 120, n. 11 OCT 2021.
Web of Science Citations: 0
Abstract

Schistosomiasis is a major public health problem that afflicts more than 240 million individuals globally, particularly in poor communities. Treatment of schistosomiasis relies heavily on a single oral drug, praziquantel, and there is interest in the search for new antischistosomal drugs. This study reports the anthelmintic evaluation of carvacryl acetate, a derivative of the terpene carvacrol, against Schistosoma mansoni ex vivo and in a schistosomiasis animal model harboring either adult (patent infection) or juvenile (prepatent infection) parasites. For comparison, data obtained with gold standard antischistosomal drug praziquantel are also presented. Initially in vitro effective concentrations of 50% (EC50) and 90% (EC90) were determined against larval and adult stages of S. mansoni. In an animal with patent infection, a single oral dose of carvacryl acetate (100, 200, or 400 mg/kg) caused a significant reduction in worm burden (30-40%). S. mansoni egg production, a process responsible for both life cycle and pathogenesis, was also markedly reduced (70-80%). Similar to praziquantel, carvacryl acetate 400 mg/kg had low efficacy in pre-patent infection. In tandem, although carvacryl acetate had interesting in vitro schistosomicidal activity, the compound exhibited low efficacy in terms of reduction of worm load in S. mansoni-infected mice. (AU)

FAPESP's process: 19/25905-2 - Preclinical evaluation for oral administration of nanostructured formulations containing drugs with anthelmintic activity
Grantee:Ana Carolina Araujo Mengarda
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 16/22488-3 - Drug repositioning for neglected diseases: identification of novel anthelmintic agents
Grantee:Josué de Moraes
Support Opportunities: Regular Research Grants
FAPESP's process: 19/25289-0 - In vitro anthelmintic activity of praziquantel and mefenamic acid nanocarreated
Grantee:Vinícius de Castro Rodrigues
Support Opportunities: Scholarships in Brazil - Scientific Initiation